SteadyMed Announces Initiation of Inter Partes Review

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
SteadyMed Announces Initiation of Inter Partes Review Proceedings by U.S. Patent and Trademark Office Against a United Therapeutics Patent

SAN RAMON, Calif., April 11, 2016 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq: STDY ), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and high-value diseases with unmet parenteral delivery needs, today announced that the Patent Trial and Appeal Board (PTAB) of the United States Patent and Trademark Office (USPTO) has initiated an inter partes review (IPR) proceeding against U.S. Patent No. 8,497,393 (the '393 patent) owned by United Therapeutics (Nasdaq: UTHR ). This patent relates to a process to further purify prostacyclin derivatives, such as treprostinil.  Treprostinil is the active pharmaceutical ingredient used in United Therapeutics' Remodulin® and SteadyMed's lead drug candidate, Trevyent®, for the treatment of Pulmonary Arterial Hypertension (PAH).

“The initiation of this IPR by PTAB is a significant decision in favor of SteadyMed. While we have an appreciation for the patent process in the U.S., we believe that the patent in question is invalid. We are pleased that the PTAB, by its action to institute the formal review process, appears to believe that there is sufficient doubt about the validity of certain claims of the ‘393 patent,” stated Jonathan Rigby, President and Chief Executive Officer of SteadyMed. “We look forward to submitting our New Drug Application (NDA) for Trevyent, which has been granted Orphan Designation, later this year. We are eager to see patients benefit from Trevyent, if approved, we have begun early preparation work for commercialization and believe that we will make significant in-roads to the PAH market.”

Statistics on IPRs report that from 2012-2015, for cases decided by final decision after institution, 74% were resolved by finding all claims unpatentable, cancelling all claims and rendering the patent invalid, 14% were resolved by finding some claims unpatentable and cancelling those claims and 12% were resolved by finding all claims patentable with the patent remaining valid.

SteadyMed will hold an Analyst and Investor reception on April 20 th , 2016 from 8a.m.-10.a.m. at the Lotte New York Palace, New York City.

Fernando Torres , M.D ., Professor of Medicine at UT Southwestern Medical Center and Director of the Lung Transplant and Pulmonary Hypertension Programs at Clements University Hospital, will make an informative presentation on Pulmonary Arterial Hypertension and the therapies used to treat it. Jonathan Rigby, President and CEO of SteadyMed, Ltd. will provide a corporate update and overview of Trevyent ® ; a Pre-NDA stage drug product being developed to create a wave in the Pulmonary Arterial Hypertension market.

Attendance is by invitation only and space is limited - To pre-register for the event, please contact David Burke of The Ruth Group at dburke@theruthgroup.com, or call 646-536-7009.

About SteadyMed

SteadyMed Ltd. is a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and high value diseases with unmet parenteral delivery needs. The company's lead drug product candidate is Trevyent ® , a development stage drug product that combines SteadyMed's PatchPump technology with treprostinil, a vasodilatory prostacyclin analogue to treat pulmonary arterial hypertension (PAH). PatchPump is a proprietary, disposable, parenteral drug administration platform that is prefilled and preprogrammed at the site of manufacture. SteadyMed intends to commercialize Trevyent in the U.S. and has signed an exclusive license and supply agreement with Cardiome Pharma Corp. for the commercialization of Trevyent in Europe, Canada and the Middle East. SteadyMed has offices in San Ramon, California and Rehovot, Israel. For additional information about SteadyMed please visit www.steadymed.com .

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, statements concerning the potential outcome of inter partes review of U.S. Patent No. 8,497,393, the company's ability to advance its development-stage product candidates, including Trevyent, statements about the potential benefits of our development-stage product candidates and our PatchPump technology, and statements about our ability to obtain and maintain regulatory approval of our development-stage product candidates. Forward-looking statements reflect the company's current views with respect to certain current and future events and are subject to various risks, uncertainties and assumptions that could cause actual results to differ materially. Risks and uncertainties include, but are not limited to, the outcome of inter partes review of U.S. Patent No. 8,497,393, the risk that Trevyent does not demonstrate clinical superiority to existing parenteral treprostinil products, that Trevyent is not approved for commercialization by the FDA and the risk that drug development involves a lengthy and expensive process with uncertain outcome. The risks, uncertainties and assumptions referred to above are discussed in detail in our reports filed with the Securities and Exchange Commission, including our Annual Report on Form 10-K filed March 29 th , 2016. The company does not undertake to publicly update or revise any forward-looking statements to reflect events or circumstances that may arise after the date hereof except as may be required by law.

CONTACT: Contacts: Marylyn Rigby Senior Director, Investor Relations and Marketing 925-272-4999 mrigby@steadymed.com The Ruth Group David Burke dburke@theruthgroup.com 646-536-7009

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Duetti, CesiumAstro, and a Busy NYSE Capital Morning

Updated Category News Views 78

Three very different piles of money are jamming up the November 20 NYSE slate, and that contrast is the whole point. Private music catalogs, space-and-defense communications, and a new stock-and-bond ETF do not belong in the same bucket. Yet all three are competing for investor attention before the opening bell, alongside Danaos Corporation's 20th listing anniversary....

Continue Reading
Simmons Clarifies Texas Loan Exposure, But Risks Remain

Updated Category News Views 50

A $45 million discrepancy is not a rounding error, and Simmons First National has every reason to swat it down hard. The bank says recent reporting overstated financing tied to a Texas multifamily development at $133 million. Its stated total is roughly $88 million, with about $44 million participated to another financial institution. For shareholders in NASDAQ:SFNC, that...

Continue Reading
Story Cannabis Bets on Neighborly Thanksgiving Outreach

Updated Category News Views 58

A frozen turkey is not a grand strategy deck, thank goodness; it is dinner for a household that might be feeling the squeeze. Story Cannabis plans to hand out 840 of them on Tuesday, Nov. 24, splitting the giveaway between Columbus and Cleveland with former Ohio State and Dallas Cowboys running back Michael Wiley joining employees and volunteers. In a cannabis business...

Continue Reading
North Richland Hills Bets on Its Visitor Momentum Now

Updated Category News Views 65

A crowded family attraction map is a nice problem for a Texas city to have, and North Richland Hills is trying to turn that pile of assets into a cleaner regional tourism machine. On Nov. 20, 2026, the city introduced “The Place You Never Outgrow,” its first destination-marketing campaign, built with Flat Five Marketing. This is not a stock story in the usual...

Continue Reading
Kinross Lawsuit Puts Round Mountain Claims Under Fire

Updated Category News Views 0

A mine can swallow a rosy forecast faster than any spreadsheet admits. That is the ugly center of the proposed securities class action involving Kinross Gold: not merely that production guidance came down, but the allegation that investors were sold too much confidence before the operational reality at Round Mountain Phase S surfaced. NYSE:KGC dropped from $27.62 on...

Continue Reading
Webster First Takes Aim at the Youth Money Literacy Gap

Updated Category News Views 39

Money mistakes get expensive long before anyone calls them mistakes. That is the uncomfortable point beneath Webster First Federal Credit Union CEO John Thomasian's November 20, 2026 discussion of financial literacy: plenty of young adults are entering the real financial world with a card, a loan offer, and a phone full of banking apps, but no sturdy framework for using...

Continue Reading
TOP-REAL Tests Digital Monitoring in HER2 Cancer Care

Updated Category News Views 116

A cancer treatment can be extraordinarily potent and still get derailed by what happens on an ordinary Tuesday at home. That unglamorous gap between clinic visits is the whole point of TOP-REAL, a phase II academic study presented at ESMO AI & Digital Oncology 2026. Solti and its European partners are testing whether closer digital follow-up can catch trouble early enough...

Continue Reading
Flair's New Aviation Alliance Offers Options, Not Orders

Updated Category News Views 55

Aircraft shortages have a funny way of turning vague partnerships into very useful insurance policies. Flair Airlines, Phoenix Aviation Capital and Avia Solutions Group announced a Strategic Commercial Cooperation Agreement on Nov. 19, 2026, and the sensible reading is straightforward: the Canadian value carrier wants more ways to solve capacity and operational problems...

Continue Reading
Charter Investigation Puts ACP Exit Claims Under Lens

Updated Category News Views 13

Charter’s ACP hangover has grown from an operating headache into a governance question. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether Charter Communications officers or directors breached fiduciary duties or otherwise broke state or federal law. That is not a finding of wrongdoing, and investors ought to keep that distinction...

Continue Reading
Arizona's Dry Climate Puts Scalp Health Under Stress

Updated Category News Views 65

Desert weather is unforgiving, and apparently the scalp does not get a pass. In a Nov. 20, 2026 discussion, Scottsdale and Tucson hair-restoration physician Dr. Sharon A. Keene frames Arizona hair concerns around something easy to overlook: the condition of the skin beneath the hair. That is a more sensible starting point than treating every strand in the shower like it...

Continue Reading

Top 5 Most Recently Viewed Articles

BlackBerry QNX and Pi Square Join Forces to Advance Indian Tech

Updated Category News Views 333

BlackBerry QNX Partners with Pi Square Technologies BlackBerry Limited (NYSE: BB) is experiencing a notable increase in share prices, reflecting growing investor confidence. Expanding Horizons for Engineers Recently, BlackBerry’s QNX division announced an exciting multi-year collaboration with Pi Square Technologies. This initiative aims to train thousands of engineers...

Continue Reading
Investors Urged to Act: Investigating DexCom Securities Claims

Updated Category News Views 67

Understanding the Ongoing Investigations into DexCom Faruqi & Faruqi, LLP, a prominent national securities law firm, is currently investigating potential claims on behalf of investors affected by losses in DexCom, Inc. (NASDAQ: DXCM). This inquiry is a direct response to significant concerns raised about the company's business practices and market performance. The Scope...

Continue Reading
Legal Battle Heats Up for Michigan Auto Attorney Over CURE

Updated Category News Views 299

Michigan Attorney Faces Legal Challenges Amid CURE Controversy In a recent turn of events, an attorney from Michigan is experiencing the challenges of navigating legal waters after speaking out against CURE Auto Insurance. The attorney, Steven M. Gursten, along with his firm Michigan Auto Law, is embroiled in lawsuits that highlight serious concerns about consumer...

Continue Reading
Investors of Joint Stock Company Kaspi.kz (KSPI) Take Action Now

Updated Category News Views 120

Investors of Joint Stock Company Kaspi.kz (NASDAQ: KSPI) Take Action Attention investors of Joint Stock Company Kaspi.kz, also known as KSPI! A recent report has raised serious concerns regarding the company's activities, prompting investors who have experienced losses to consider their options in filing a securities fraud lawsuit. These troubling developments are crucial...

Continue Reading
Investors Guide: Urgent Action Needed for Western Asset Fund

Updated Category News Views 130

Introduction to the Class Action The Rosen Law Firm, a prominent name in investor rights advocacy, is urging investors in the Western Asset Management Company mutual funds to take action before an important deadline. If you invested in the 'Western Asset US Core Bond Fund' or the 'Western Asset Core Plus Bond Fund' during the designated class period, this message is...

Continue Reading